Conflicts of interest in biomedical publications: Considerations for authors, peer reviewers, and editors

Croatian Medical Journal

Volumn 54, Issue 6, 2013, Pages 600-608

  Gasparyan, Armen Yuri ^a   Ayvazyan, Lilit ^b   Akazhanov, Nurbek A ^c   Kitas, George D ^a,d  

^a RUSSELLS HALL HOSPITAL   (United Kingdom)

^b YEREVAN STATE MEDICAL UNIVERSITY   (Armenia)

^c ASFENDIYAROV KAZAKH NATIONAL MEDICAL UNIVERSITY   (Kazakhstan)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; AUTHOR; CONFLICT OF INTEREST; EDITOR; MEDICAL LITERATURE; PEER REVIEW; RHEUMATOLOGY;

BIOMEDICAL RESEARCH; CONFLICT OF INTEREST; DATABASES, FACTUAL; DISCLOSURE; GUIDELINES AS TOPIC; HUMANS; PEER REVIEW; PERIODICALS AS TOPIC; REPRODUCIBILITY OF RESULTS;

EID: 84892423724     PISSN: 03539504     EISSN: 13328166     Source Type: Journal    
DOI: 10.3325/cmj.2013.54.600     Document Type: Article

References (63)

1. Marcovitch H, Barbour V, Borrell C, Bosch F, Fernández E, Macdonald H, et al; Esteve Foundation Discussion Group. Conflict of interest in science communication: more than a financial issue. Report from Esteve Foundation Discussion Group, April 2009. Croat Med J. 2010;51:7-15. Medline:20162740 doi:10.3325/cmj.2010.51.7
2. Tonelli MR. Conflict of interest in clinical practice. Chest. 2007;132:664-70. Medline:17699138 doi:10.1378/chest.07-0315
3. Declaration of competing interests. Available from: http://www.bmj.com/about-bmj/resources-authors/forms-policies-andchecklists/declaration-competing-interests. Accessed: December 5, 2013.
4. LoB, Wolf LE, Berkeley A. Conflict-of-interest policies for investigators in clinical trials. N Engl J Med. 2000;343:1616-20. Medline:11096170 doi:10.1056/NEJM200011303432206
5. Kjaergard LL, Als-Nielsen B. Association between competing interests and authors' conclusions: epidemiological study of randomised clinical trials published in the BMJ. BMJ. 2002;325:249. Medline:12153921 doi:10.1136/bmj.325.7358.249
6. Conen D, Torres J, Ridker PM. Differential citation rates of major cardiovascular clinical trials according to source of funding: a survey from 2000 to 2005. Circulation. 2008;118:1321-7. Medline:18779441 doi:10.1161/CIRCULATIONAHA.108.794016
7. Charlton BG. Conflicts of interest in medical science: peer usage, peer review and 'CoI consultancy'. Med Hypotheses. 2004;63:181-6. Medline:15236772 doi:10.1016/j.mehy.2004.06.001
8. Ruiz MA. The consequence of stacking by Brazilian journals. Rev Bras Hematol Hemoter. 2013;35:223-4. Medline:24106431 doi:10.5581/1516-8484.20130092
9. Schneider N, Lingner H, Schwartz FW. Disclosing conflicts of interest in German publications concerning health services research. BMC Health Serv Res. 2007;7:78. Medline:17543111 doi:10.1186/1472-6963-7-78
10. Simundic AM. Editing a scientific journal in Croatia: the case of Biochemia Medica. Eur Sci Ed. 2012;38:69-70.
11. Simundic AM. Biochemia Medica indexed in Medline. Biochem Med (Zagreb). 2012;22:5-6. Medline:22384514 doi:10.11613/BM.2012.001
12. Smith R. Medical journals are an extension of the marketing arm of pharmaceutical companies. PLoS Med. 2005;2:e138. Medline:15916457 doi:10.1371/journal.pmed.0020138
13. Haivas I, Schroter S, Waechter F, Smith R, editors. ' declaration of their own conflicts of interest. CMAJ. 2004;171:475-6. Medline:15337729 doi:10.1503/cmaj.1031982
14. Alfonso F, Timmis A, Pinto FJ, Ambrosio G, Ector H, Kulakowski P, et al; Editors' Network European Society of Cardiology Task Force. Conflict of interest policies and disclosure requirements among European Society of Cardiology National Cardiovascular Journals. Heart. 2012;98:e1-7. Medline:22422746 doi:10.1136/heartjnl-2012-301875
15. Roundtree AK, Kallen MA, Lopez-Olivo MA, Kimmel B, Skidmore B, Ortiz Z, et al. Poor reporting of search strategy and conflict of interest in over 250 narrative and systematic reviews of two biologic agents in arthritis: a systematic review. J Clin Epidemiol. 2009;62:128-37. Medline:19013763 doi:10.1016/j. jclinepi.2008.08.003
16. Roseman M, Milette K, Bero LA, Coyne JC, Lexchin J, Turner EH, et al. Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments. JAMA. 2011;305:1008-17. Medline:21386079 doi:10.1001/jama.2011.257
17. Roseman M, Turner EH, Lexchin J, Coyne JC, Bero LA, Thombs BD. Reporting of conflicts of interest from drug trials in Cochrane reviews: cross sectional study. BMJ. 2012;345:e5155. Medline:22906823 doi:10.1136/bmj.e5155
18. Lenzer J. Why we can't trust clinical guidelines. BMJ. 2013;346:f3830. Medline:23771225 doi:10.1136/bmj.f3830
19. Choudhry NK, Stelfox HT, Detsky AS. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA. 2002;287:612-7. Medline:11829700 doi:10.1001/jama.287.5.612
20. Norris SL, Holmer HK, Ogden LA, Burda BU, Fu R. Conflicts of Interest among Authors of Clinical Practice Guidelines for Glycemic Control in Type 2 Diabetes Mellitus. PLoS ONE. 2013;8:e75284. Medline:24155870 doi:10.1371/journal.pone.0075284
21. Pendleton A, Arden N, Dougados M, Doherty M, Bannwarth B, Bijlsma JW, et al. EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2000;59:936-44. Medline:11087696 doi:10.1136/ard.59.12.936
22. Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther KP, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2005;64:669-81. Medline:15471891 doi:10.1136/ard.2004.028886
23. Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC Jr, Dijkmans B, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2006;65:442-52. Medline:16126791 doi:10.1136/ard.2005.041137
24. Hoes JN, Jacobs JW, Boers M, Boumpas D, Buttgereit F, Caeyers N, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2007;66:1560-7. Medline:17660219 doi:10.1136/ard.2007.072157
25. Zhang W, Doherty M, Leeb BF, Alekseeva L, Arden NK, Bijlsma JW, et al. EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007;66:377-88. Medline:17046965 doi:10.1136/ard.2006.062091
26. Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld F, Dougados M, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007;66:34-45. Medline:16396980 doi:10.1136/ard.2005.044354
27. Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, et al. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis. 2008;67:1656-62. Medline:18245110 doi:10.1136/ard.2007.080432
28. Carville SF, Arendt-Nielsen S, Bliddal H, Blotman F, Branco JC, Buskila D, et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis. 2008;67:536-41. Medline:17644548 doi:10.1136/ard.2007.071522
29. Bertsias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis. 2008;67:195-205. Medline:17504841 doi:10.1136/ard.2007.070367
30. Zhang W, Doherty M, Leeb BF, Alekseeva L, Arden NK, Bijlsma JW, et al. EULAR evidence-based recommendations for the diagnosis of hand osteoarthritis: report of a task force of ESCISIT. Ann Rheum Dis. 2009;68:8-17. Medline:18250111 doi:10.1136/ard.2007.084772
31. Kiltz U, van der Heijde D, Mielants H, Feldtkeller E, Braun J. PARE/EULAR patient initiative group. ASAS/EULAR recommendations for the management of ankylosing spondylitis: the patient version. Ann Rheum Dis. 2009;68:1381-6. Medline:18930993 doi:10.1136/ard.2008.096073
32. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69:964-75. Medline:20444750 doi:10.1136/ard.2009.126532
33. Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69:325-31. Medline:19773290 doi:10.1136/ard.2009.113696
34. Bertsias GK, Ioannidis JP, Aringer M, Bollen E, Bombardieri S, Bruce IN, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010;69:2074-82. Medline:20724309 doi:10.1136/ard.2010.130476
35. Heijstek MW, Ott de Bruin LM, Bijl M, Borrow R, van der Klis F, Kone-Paut I, et al. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis. 2011;70:1704-12. Medline:21813547 doi:10.1136/ard.2011.150193
36. van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011;70:414-22. Medline:21131643 doi:10.1136/ard.2010.137216
37. van der Heijde D, Sieper J, Maksymowych WP, Dougados M, Burgos-Vargas R, Landewe R, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis. 2011;70:905-8. Medline:21540200 doi:10.1136/ard.2011.151563
38. Zhang W, Doherty M, Pascual E, Barskova V, Guerne PA, Jansen TL, et al. EULAR recommendations for calcium pyrophosphate deposition. Part II: management. Ann Rheum Dis. 2011;70:571-5. Medline:21257614 doi:10.1136/ard.2010.139360
39. Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70:896-904. Medline:21540199 doi:10.1136/ard.2011.151027
40. Hamburger M, Baraf HS, Adamson TC III, Basile J, Bass L, Cole B, et al. 2011 Recommendations for the diagnosis and management of gout and hyperuricemia. Postgrad Med. 2011;123(6 Suppl 1):3-36. Medline:22156509 doi:10.3810/pgm.2011.11.2511
41. Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann 608 SCIENCE COMMUNICATION Croat Med J. 2013;54:600-8 www.cmj.hr Rheum Dis. 2012;71:1771-82. Medline:22851469 doi:10.1136/annrheumdis-2012-201940
42. Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012;71:4-12. Medline:21953336 doi:10.1136/annrheumdis-2011-200350
43. Fernandes L, Hagen KB, Bijlsma JW, Andreassen O, Christensen P, Conaghan PG, et al. EULAR recommendations for the nonpharmacological core management of hip and knee osteoarthritis. Ann Rheum Dis. 2013;72:1125-35. Medline:23595142 doi:10.1136/annrheumdis-2012-202745
44. Colebatch AN, Edwards CJ, Ostergaard M, van der Heijde D, Balint PV, D'Agostino MA, et al. EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis. 2013;72:804-14. Medline:23520036 doi:10.1136/annrheumdis-2012-203158
45. Duru N, van der Goes MC, Jacobs JW, Andrews T, Boers M, Buttgereit F, et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2013;72:1905-13. Medline:23873876 doi:10.1136/annrheumdis- 2013-203249
46. Sivera F, Andres M, Carmona L, Kydd AS, Moi J, Seth R, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis. 2013. Epub ahead of print. Medline:23868909 doi:10.1136/annrheumdis-2013-203325
47. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological diseasemodifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2013. Epub ahead of print. Medline:24161836 doi:10.1136/annrheumdis-2013-204573
48. Romain PL. Ethics: Investigators' interests: what should trial participants be told? Nat Rev Rheumatol. 2010;6:70-1. Medline:20125171 doi:10.1038/nrrheum.2009.264
49. Perlis CS, Harwood M, Perlis RH. Extent and impact of industry sponsorship conflicts of interest in dermatology research. J Am Acad Dermatol. 2005;52:967-71. Medline:15928613 doi:10.1016/j. jaad.2005.01.020
50. Jagsi R, Sheets N, Jankovic A, Motomura AR, Amarnath S, Ubel PA. Frequency, nature, effects, and correlates of conflicts of interest in published clinical cancer research. Cancer. 2009;115:2783-91. Medline:19434666 doi:10.1002/cncr.24315
51. Kang BH, Moon JY, Chang Y, Koo YM, Koh Y. Current levels of conflict of interest disclosure in medical publications from Korea. J Korean Med Sci. 2013;28:978-82. Medline:23853478 doi:10.3346/jkms.2013.28.7.978
52. Singapore Statement on Research Integrity. Available from: http://www.singaporestatement.org/statement.html. Accessed: December 5, 2013.
53. Roles and responsibilities of authors, contributors, reviewers, editors, publishers, and owners: author responsibilities - conflicts of interest. Available from: http://www.icmje.org/roles_b.html. Accessed: December 5, 2013.
54. ICMJE Form for Disclosure of Potential Conflicts of Interest. Available from: http://www.icmje.org/coi_disclosure.pdf. Accessed: December 5, 2013.
55. Conflict of Interest in Peer-Reviewed Medical Journals. Available from: http://www.wame.org/conflict-of-interest-in-peer-reviewedmedical-journals. Accessed: December 5, 2013.
56. Code of Conduct and Best Practice Guidelines for Journal Editors. Available from: http://publicationethics.org/files/Code_of_ conduct_for_journal_editors_Mar11.pdf. Accessed: December 5, 2013.
57. A brief overview on Conflict of Interests. Available from: http://ori. hhs.gov/plagiarism-35. Accessed: December 5, 2013.
58. CSE's White Paper on Promoting Integrity in Scientific Journal Publications. Available from: http://www.councilscienceeditors.org/i4a/pages/index.cfm?pageid=3636#213. Accessed: December 5, 2013.
59. E ASE Guidelines for Authors and Translators of Scientific Articles to Be Published in English. Available from: http://www.ease.org.uk/sites/default/files/ease_guidelines-june2013-english.pdf. Accessed: December 5, 2013.
60. Drazen JM, de Leeuw PW, Laine C, Mulrow C, Deangelis CD, Frizelle FA, et al. Toward more uniform conflict disclosures: the Updated ICMJE conflict of interest reporting form. Croat Med J. 2010;51:287-8. Medline:20718080 doi:10.3325/cmj.2010.51.287
61. Baethge C. The effect of a conflict of interest disclosure form using closed questions on the number of positive conflicts of interest declared - a controlled study. PeerJ. 2013;1:e128. Medline:24024081 doi:10.7717/peerj.128
62. Simera I, Altman DG. Reporting medical research. Int J Clin Pract. 2013;67:710-6. Medline:23656235 doi:10.1111/ijcp.12168
63. MacKenzie CR, Meltzer M, Kitsis EA, Mancuso CA. Ethical challenges in rheumatology: a survey of the American College of Rheumatology membership. Arthritis Rheum. 2013;65:2524-32. Medline:23839952